Cargando…

Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial

INTRODUCTION: The German Hodgkin Study Group (GHSG) HD17 trial established the omission of radiotherapy (RT) for patients with early-stage unfavorable Hodgkin lymphoma being PET-negative after 2 cycles of BEACOPP escalated plus 2 cycles of ABVD. This patient group reveals heterogeneity in characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oertel, Michael, Hering, Dominik, Baues, Christian, Kittel, Christopher, Fuchs, Michael, Kriz, Jan, Kröger, Kai, Vordermark, Dirk, Herfarth, Klaus, Engenhart-Cabillic, Rita, Lukas, Peter, Haverkamp, Uwe, Borchmann, Peter, Eich, Hans Theodor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196378/ https://www.ncbi.nlm.nih.gov/pubmed/37213291 http://dx.doi.org/10.3389/fonc.2023.1183906

Ejemplares similares

P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
por: Oertel, Michael, et al.
Publicado: (2022)

P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
por: Oertel, Michael, et al.
Publicado: (2022)

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
por: Oertel, Michael, et al.
Publicado: (2022)

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022)

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
por: Bröckelmann, Paul J., et al.
Publicado: (2022)

Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients – An Analysis of GHSG HD14- and HD17-Patients
por: Rosenbrock, Johannes, et al.
Publicado: (2021)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic: Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance
por: Oertel, M., et al.
Publicado: (2020)

Stellenwert der Radiotherapie bei Morbus Hodgkin in intermediären Stadien: Ergebnisse der HD17-Studie (GHSG)
por: Süß, Christoph, et al.
Publicado: (2021)

Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin’s lymphoma
por: Pepper, Niklas Benedikt, et al.
Publicado: (2020)

The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists
por: Oertel, Michael, et al.
Publicado: (2023)

A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma
por: Scobioala, Sergiu, et al.
Publicado: (2019)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
por: Bröckelmann, Paul, et al.
Publicado: (2023)

Hybrid volumetric modulated arc therapy for hypofractionated radiotherapy of breast cancer: a treatment planning study
por: Venjakob, Alexander, et al.
Publicado: (2020)

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study
por: Herfarth, Klaus, et al.
Publicado: (2018)

Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma
por: Peuker, Leonie, et al.
Publicado: (2022)

Verschlechterung der Lebensqualität von Patienten mit Morbus Hodgkin in den folgenden 5 Jahren nach abgeschlossener Therapie: Langzeitdaten aus den Studien HD13, HD14 und HD15
por: Vordermark, Dirk
Publicado: (2021)

The Lymph-Sparing Quotient: A Retrospective Risk Analysis on Extremity Radiation for Soft Tissue Sarcoma Treatment
por: Sarif, Iqbal, et al.
Publicado: (2021)

Biophysical Analysis of Acute and Late Toxicity of Radiotherapy in Gastric Marginal Zone Lymphoma—Impact of Radiation Dose and Planning Target Volume
por: Reinartz, Gabriele, et al.
Publicado: (2021)

A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma
por: Scobioala, Sergiu, et al.
Publicado: (2016)

Pulmonary Toxicity after Total Body Irradiation—An Underrated Complication? Estimation of Risk via Normal Tissue Complication Probability Calculations and Correlation with Clinical Data
por: Oertel, Michael, et al.
Publicado: (2021)

Students’ learning behavior in digital education for radiation oncology
por: Vorwerk, Hilke, et al.
Publicado: (2021)

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
por: van Heek, Lutz, et al.
Publicado: (2022)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma
por: Oertel, Michael, et al.
Publicado: (2019)

Bridging vor CAR T-Zell-Therapie – eine neue Indikation der Strahlentherapie?
por: Oertel, Michael, et al.
Publicado: (2021)

Strahlentherapeutische Behandlung von Leukämien
por: Oertel, Michael, et al.
Publicado: (2022)

Strahlentherapeutische Behandlung von Leukämien
por: Oertel, Michael, et al.
Publicado: (2022)

Kardiovaskuläre Risikoevaluation in der Behandlung des Hodgkin-Lymphoms – auf dem Weg zur individualisierten Planung?
por: Oertel, Michael, et al.
Publicado: (2023)

Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease
por: Kriz, Jan, et al.
Publicado: (2013)

Dosimetric robustness against setup errors in charged particle radiotherapy of skull base tumors
por: Ammazzalorso, Filippo, et al.
Publicado: (2014)

A phantom based evaluation of the dose prediction and effects in treatment plans, when calculating on a direct density CT reconstruction
por: Flatten, Veronika, et al.
Publicado: (2020)

The fast calibration model for dosimetry with an electronic portal imaging device
por: Schade, Stephanie, et al.
Publicado: (2022)

Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin’s disease
por: Lautenschlaeger, S., et al.
Publicado: (2019)

Sekundärmalignome nach Ganzkörperbestrahlung pädiatrischer Leukämiepatienten – eine kritische Re-Evaluation der multizentrischen ALL-SCT-BFM-2003-Studie
por: Knaack, Christian, et al.
Publicado: (2023)

Making the right software choice for clinically used equipment in radiation oncology
por: Vorwerk, Hilke, et al.
Publicado: (2014)

Radiotherapy in Follicular Lymphoma Staged by (18)F-FDG-PET/CT: A German Monocenter Study
por: Karsten, Imke E., et al.
Publicado: (2021)

Siah1 proteins enhance radiosensitivity of human breast cancer cells
por: He, Hai-Tao, et al.
Publicado: (2010)

Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
por: Santiago, Alina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5nohb65g9ep4m8kssvpn1jipbk